Dr. Marcus Butler
Contact
Dr. Marcus Butler
Co-Leader
Immuno-oncology Translational Research Initiative (ACTION)
Immuno-oncology Translational Research Initiative (ACTION)
Co-Leader
Immuno-oncology Translational Research Initiative (ACTION)
Immuno-oncology Translational Research Initiative (ACTION)
Dr. Marcus Butler is the Clinical Co-Leader of OICR’s Immuno-oncology Translational Research Initiative. His expertise includes clinical trials in a variety of immune therapies including adoptive T-cell therapy and checkpoint blockade.
Dr. Butler is the Clinical Head of the Immune Monitoring Team at the Princess Margaret Cancer Centre, where his group performs a wide variety of immunologic assays to examine the impact of therapies on immune phenotype and function.
Before joining the Princess Margaret Cancer Centre, he was an Instructor in Medicine at Harvard Medical School and a Clinical Fellow in Medicine at the Dana-Farber Cancer Institute.
Experience & Education
- Medical Oncology Fellowship, Dana-Farber/Partners CancerCare
- Internal Medicine Residency, Johns Hopkins Hospital
- MD, Yale University School of Medicine
- BA, Rice University
Current Affiliations
- Co-Leader, Immuno-oncology Translational Research Initiative
- Medical Oncology Disease Site Lead for Melanoma/Skin Oncology, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre
- Assistant Professor, Department of Medicine, University of Toronto
- Associate Member, Department of Immunology, University of Toronto
Select Publications
- Nguyen LT, Saibil SD, Sotov V, …, Butler MO. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2. Cancer Immunol Immunother. 2019; 68:773-785.
- Kagoya Y, Nakatsugawa M, Yamashita Y, …, Butler MO, …, Hirano N. BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models. J Clin Invest. 2016; 126(9):3479-94.
- Nakatsugawa M, Rahman MA, Yamashita Y, …, Butler MO, Hirano N. CD4(+) and CD8(+) TCRβ repertoires possess different potentials to generate extraordinarily high-avidity T cells. Sci Rep. 2016; 6:23821.
- Nakatsugawa M, Yamashita Y, Ochi T, …, Butler MO, Hirano N. Specific roles of each TCR hemichain in generating functional chain-centric TCR. J Immunol. 2015; 194(7):3487-500.
- Butler MO, Friedlander P, Milstein MI, …, Hirano N. Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med. 2011; 3(80):80ra34.
See Dr. Butler’s recent publications on PubMed or Google Scholar.
Research Areas
Disease Areas
Opportunities to Collaborate
To collaborate with Dr. Butler, please contact him directly.
Visit OICR’s Collaborative Research Resources directory for more opportunities to collaborate with OICR researchers.
Looking Ahead
Receive the latest news, event invites, funding opportunities and more from the Ontario Institute for Cancer Research.